Enovis (NYSE:ENOV) Price Target Raised to $42.00

Enovis (NYSE:ENOV) had its price objective upped by analysts at BTIG Research from $36.00 to $42.00 in a research report issued on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. BTIG Research‘s price target would indicate a potential upside of 51.30% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a research report on Wednesday, July 29th. UBS Group reiterated a “buy” rating and issued a $44.00 price objective on shares of Enovis in a research note on Monday, October 5th. Citigroup restated a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Needham & Company LLC decreased their target price on shares of Enovis from $52.00 to $34.00 and set a “buy” rating on the stock in a research report on Monday, October 12th. Finally, Citizens Jmp dropped their price target on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Enovis presently has an average rating of “Moderate Buy” and an average price target of $38.00.

Enovis Stock Performance

Shares of NYSE ENOV traded up $3.34 during trading hours on Thursday, reaching $27.76. 2,854,814 shares of the stock were exchanged, compared to its average volume of 1,257,060. The firm has a market capitalization of $1.60 billion, a price-to-earnings ratio of -1.43 and a beta of 1.31. The stock’s fifty day simple moving average is $19.79 and its 200 day simple moving average is $23.05. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. Enovis has a 52 week low of $16.70 and a 52 week high of $32.41.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.88 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.77 by $0.11. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The business had revenue of $558.73 million during the quarter, compared to the consensus estimate of $557.12 million. During the same period in the previous year, the company posted $0.75 EPS. The firm’s quarterly revenue was up 1.8% on a year-over-year basis. Sell-side analysts predict that Enovis will post 3.15 EPS for the current year.

Insider Activity

In related news, CEO Damien Mcdonald bought 13,035 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were purchased at an average price of $19.15 per share, with a total value of $249,620.25. Following the completion of the purchase, the chief executive officer owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, insider Oliver Engert bought 2,660 shares of Enovis stock in a transaction on Friday, September 4th. The shares were acquired at an average cost of $18.80 per share, for a total transaction of $50,008.00. Following the completion of the acquisition, the insider directly owned 63,898 shares in the company, valued at approximately $1,201,282.40. The trade was a 4.34% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 23,293 shares of company stock worth $449,599 over the last ninety days. 2.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Enovis

A number of institutional investors and hedge funds have recently modified their holdings of the business. IFP Advisors Inc increased its stake in shares of Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares in the last quarter. Allworth Financial LP bought a new position in shares of Enovis in the 2nd quarter worth $36,000. Integrated Wealth Concepts LLC bought a new stake in Enovis during the second quarter worth about $39,000. Public Employees Retirement System of Ohio purchased a new position in shares of Enovis during the 2nd quarter valued at about $48,000. Finally, SBI Securities Co. Ltd. purchased a new stake in Enovis in the third quarter worth approximately $55,000. 98.45% of the stock is currently owned by institutional investors.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported adjusted earnings of $0.88 per share, above analyst estimates of $0.76–$0.77 and up from $0.75 a year earlier. The earnings beat is a key catalyst for the stock’s advance. Article: Enovis Q3 Earnings and Revenues Beat Estimates
• Positive Sentiment: The company announced a $200 million share buyback, which could support demand for shares and signals a commitment to returning capital to shareholders. Article: Enovis announces a $200 million equity buyback
• Neutral Sentiment: Quarterly revenue was $558.73 million, slightly above analyst expectations of $557.12 million and 1.8% higher year over year. The modest growth and largely in-line revenue provide a less powerful catalyst than the earnings beat. Article: Enovis announces third-quarter 2026 results

Enovis Company Profile

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.